KA/EN
Register
Medicines reference
Search
Search
Product

Euphyllin

Favourites

Aminophylline · Biopolus, Usolye-Sibirsky Chemical-Pharmaceutical Plant

3 forms: solution, tablet. In force in Georgia: 1 of 3 (human register).

Forms and doses1 of 3 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Choose species and weight; the matching row will be highlighted.
Form Species Dose Frequency Georgia
24 mg/ml (2.4%), Solution - No label dose in the reference yet - Georgia Suspended
Suspended or cancelled
Human (Ministry of Health, RAMA)
№ რ-031590, რ-031592, რ-039831
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Euphyllin 24 mg/ml (2.4%), Solution

5 ml ampoule, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Monitored IV rescue treatment of acute, clinically important bronchospasm when inhaled beta2-agonist treatment is unavailable, inadequate or cannot be delivered; not routine first-line or chronic-airway treatment.
Not rateable
No numerical score assigned
vetman assessment

Euphyllin

24 mg/ml (2.4%), 5 ml ampoule, human medicine
Assessed clinical scopeDog · Monitored IV rescue treatment of acute, clinically important bronchospasm when inhaled beta2-agonist treatment is unavailable, inadequate or cannot be delivered; not routine first-line or chronic-airway treatment. · Intravenous
Care settingEmergency or hospital care with venous access, controlled slow infusion, ECG, blood-pressure and electrolyte monitoring and access to serum-theophylline measurement when prior exposure or repeated dosing makes it relevant
vetman score Not rateable No numerical score assigned
Evidence confidence: Low Georgia: Suspended · № რ-031590, რ-031592, რ-039831 · Verified on 15 Oct 2026 Off-label use
Not rateable

This 5 ml catalogue row does not identify one exact medicinal product. It has no manufacturer or exact public label, while its Georgian market record combines three suspended authorisations under Euphyllin/Euphylline names and different validity dates. The concentration and pack alone cannot establish which composition, dossier, holder and safety information belong to the ampoule, so a numerical product rating would be misleading.

Aminophylline itself has a narrow, evidence-supported rescue role in monitored acute bronchospasm, but that ingredient-level evidence cannot identify or validate this unresolved 5 ml product. Confirm the manufacturer, authorisation number and exact current label before use; do not transfer the Biopolus or another 24–25 mg/ml product score to it.

Important safety and use flags

  • Administer intravenously only as a controlled slow injection or infusion; never give a rapid bolus. A canine PK comparison produced a substantially lower immediate theophylline concentration with a 15-minute infusion than with a 30-second bolus.
  • Aminophylline has a narrow therapeutic index. Before a loading dose, establish recent oral or injectable theophylline/aminophylline exposure whenever possible; monitor ECG, perfusion, blood pressure, electrolytes and clinical toxicity, and measure serum theophylline when prior exposure, repeated dosing or impaired clearance makes accumulation plausible.
  • Avoid or use only after a compelling benefit-risk decision in active tachyarrhythmia, uncontrolled seizure disorder, active peptic ulceration or known hypersensitivity to theophyllines/ethylenediamine. Fever, shock, heart failure, hepatic disease and severe systemic illness can reduce clearance and require extra caution.
  • Do not combine with another xanthine preparation unless total exposure and serum concentration are deliberately managed. Concurrent aminophylline plus theophylline from another product or route can produce serious additive toxicity.
  • Fluoroquinolones, macrolides, cimetidine, propranolol and several other inhibitors can raise theophylline exposure; phenobarbital and other enzyme inducers can lower it. Review the full medication list, avoid high-risk combinations when possible and use serum monitoring/dose adjustment when unavoidable.
  • Beta2 agonists, epinephrine and other sympathomimetics may add tachyarrhythmia and hypokalaemia risk. They may still be clinically indicated in an emergency, but combine only with ECG, electrolyte and haemodynamic monitoring rather than assuming bronchodilator effects are simply additive.
  • Aminophylline solutions are alkaline and have important admixture incompatibilities. Do not mix or use a Y-site with another medicine until compatibility has been verified for the exact concentrations and diluent from a current hospital source.
  • This is a rescue bronchodilator, not treatment of airway inflammation, anaphylactic shock, infection, pulmonary oedema or another cause of respiratory distress. Provide oxygen and cause-directed treatment; inhaled beta2 agonists are generally preferred when they can be delivered effectively.
  • Use lean/appropriate body weight, verify that the vial strength is expressed as aminophylline rather than theophylline equivalent, and calculate both milligrams and millilitres independently. Stop or slow administration and reassess vomiting, marked agitation/tremor, hypotension, tachyarrhythmia or seizure activity.
  • Safety of this exact human presentation in pregnant or lactating bitches/queens, neonates and breeding animals is not established. Use only when the monitored rescue benefit clearly outweighs the uncertainty; verify the exact product label, excipients, storage and single-use/discard instructions before administration.
Assessment sources
  1. Euphyllin 5 ml GE audit2026
  2. Veterinary aminophylline register audit2026
  3. MSD Vet Manual 20242024
  4. MSD emergency triage2026
  5. Canine/feline triage review2024
  6. Aminophylline injection SmPC2026
  7. Canine IV aminophylline infusion PK2000
  8. Canine IV aminophylline comparator PK2022
  9. Feline IV aminophylline comparator PK2007
Assessed: 22 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Cat Monitored IV rescue treatment of acute, clinically important bronchospasm when inhaled beta2-agonist treatment is unavailable, inadequate or cannot be delivered; not routine first-line or chronic-airway treatment.
Not rateable
No numerical score assigned
vetman assessment

Euphyllin

24 mg/ml (2.4%), 5 ml ampoule, human medicine
Assessed clinical scopeCat · Monitored IV rescue treatment of acute, clinically important bronchospasm when inhaled beta2-agonist treatment is unavailable, inadequate or cannot be delivered; not routine first-line or chronic-airway treatment. · Intravenous
Care settingEmergency or hospital care with venous access, controlled slow infusion, ECG, blood-pressure and electrolyte monitoring and access to serum-theophylline measurement when prior exposure or repeated dosing makes it relevant
vetman score Not rateable No numerical score assigned
Evidence confidence: Low Georgia: Suspended · № რ-031590, რ-031592, რ-039831 · Verified on 15 Oct 2026 Off-label use
Not rateable

This 5 ml catalogue row does not identify one exact medicinal product. It has no manufacturer or exact public label, while its Georgian market record combines three suspended authorisations under Euphyllin/Euphylline names and different validity dates. The concentration and pack alone cannot establish which composition, dossier, holder and safety information belong to the ampoule, so a numerical product rating would be misleading.

Aminophylline itself has a narrow, evidence-supported rescue role in monitored acute bronchospasm, but that ingredient-level evidence cannot identify or validate this unresolved 5 ml product. Confirm the manufacturer, authorisation number and exact current label before use; do not transfer the Biopolus or another 24–25 mg/ml product score to it.

Important safety and use flags

  • Administer intravenously only as a controlled slow injection or infusion; never give a rapid bolus. A canine PK comparison produced a substantially lower immediate theophylline concentration with a 15-minute infusion than with a 30-second bolus.
  • Aminophylline has a narrow therapeutic index. Before a loading dose, establish recent oral or injectable theophylline/aminophylline exposure whenever possible; monitor ECG, perfusion, blood pressure, electrolytes and clinical toxicity, and measure serum theophylline when prior exposure, repeated dosing or impaired clearance makes accumulation plausible.
  • Avoid or use only after a compelling benefit-risk decision in active tachyarrhythmia, uncontrolled seizure disorder, active peptic ulceration or known hypersensitivity to theophyllines/ethylenediamine. Fever, shock, heart failure, hepatic disease and severe systemic illness can reduce clearance and require extra caution.
  • Do not combine with another xanthine preparation unless total exposure and serum concentration are deliberately managed. Concurrent aminophylline plus theophylline from another product or route can produce serious additive toxicity.
  • Fluoroquinolones, macrolides, cimetidine, propranolol and several other inhibitors can raise theophylline exposure; phenobarbital and other enzyme inducers can lower it. Review the full medication list, avoid high-risk combinations when possible and use serum monitoring/dose adjustment when unavoidable.
  • Beta2 agonists, epinephrine and other sympathomimetics may add tachyarrhythmia and hypokalaemia risk. They may still be clinically indicated in an emergency, but combine only with ECG, electrolyte and haemodynamic monitoring rather than assuming bronchodilator effects are simply additive.
  • Aminophylline solutions are alkaline and have important admixture incompatibilities. Do not mix or use a Y-site with another medicine until compatibility has been verified for the exact concentrations and diluent from a current hospital source.
  • This is a rescue bronchodilator, not treatment of airway inflammation, anaphylactic shock, infection, pulmonary oedema or another cause of respiratory distress. Provide oxygen and cause-directed treatment; inhaled beta2 agonists are generally preferred when they can be delivered effectively.
  • Use lean/appropriate body weight, verify that the vial strength is expressed as aminophylline rather than theophylline equivalent, and calculate both milligrams and millilitres independently. Stop or slow administration and reassess vomiting, marked agitation/tremor, hypotension, tachyarrhythmia or seizure activity.
  • Safety of this exact human presentation in pregnant or lactating bitches/queens, neonates and breeding animals is not established. Use only when the monitored rescue benefit clearly outweighs the uncertainty; verify the exact product label, excipients, storage and single-use/discard instructions before administration.
Assessment sources
  1. Euphyllin 5 ml GE audit2026
  2. Veterinary aminophylline register audit2026
  3. MSD Vet Manual 20242024
  4. MSD emergency triage2026
  5. Canine/feline triage review2024
  6. Aminophylline injection SmPC2026
  7. Canine IV aminophylline infusion PK2000
  8. Canine IV aminophylline comparator PK2022
  9. Feline IV aminophylline comparator PK2007
Assessed: 22 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Composition / strength
Aminophylline24 mg/ml
Formulation Type
Solution
Administration route
Intravenous
Manufacturer
-
Registration
Georgia Suspended
Suspended or cancelled
Human (Ministry of Health, RAMA)
№ რ-031590, რ-031592, რ-039831
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
24 mg/ml (2.4%), Solution - No label dose in the reference yet - Georgia Yes, human
In force until 18 Feb 2027
Human (Ministry of Health, RAMA)
In the register: ეუფილინი 24 მგ/მლ (2.4%), 10 მლ ამპულა
№ რ-034469
Verified on: 16 Oct 2026
Details: pack, label wording, sources, registration

Euphyllin 24 mg/ml (2.4%), Solution

10 ml ampoule, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Monitored IV rescue treatment of acute, clinically important bronchospasm when inhaled beta2-agonist treatment is unavailable, inadequate or cannot be delivered; not routine first-line or chronic-airway treatment.
5.1/10
Weak evidence support
vetman assessment

Euphyllin

24 mg/ml (2.4%), 10 ml ampoule, human medicine
Assessed clinical scopeDog · Monitored IV rescue treatment of acute, clinically important bronchospasm when inhaled beta2-agonist treatment is unavailable, inadequate or cannot be delivered; not routine first-line or chronic-airway treatment. · Intravenous
Care settingEmergency or hospital care with venous access, controlled slow infusion, ECG, blood-pressure and electrolyte monitoring and access to serum-theophylline measurement when prior exposure or repeated dosing makes it relevant
vetman score 5.1/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, human · № რ-034469 · Verified on 16 Oct 2026 Off-label use

A legitimate but second-line monitored IV rescue bronchodilator, not a routine substitute for inhaled beta2 agonists or anti-inflammatory/cause-directed care. Its benefit is plausible and guideline-supported, but comparative outcome evidence is weak and the safety margin is narrow. Use only after checking prior methylxanthine exposure, infuse slowly and monitor ECG, pressure, electrolytes and toxicity.

Regulatory and scientific credibility5.0/10

The exact Biopolus 24 mg/ml 10 ml presentation has a current, sourced Georgian human registration (R-034469), identifiable manufacturer, strength and pack. No exact public product label or dossier was located, and current same-endpoint EU/EEA and GB veterinary-register searches found no aminophylline product; therefore product-specific excipients, handling and pharmacovigilance transparency remain limited and dog/cat use is off-label.

Clinical efficacy5.5/10

Current veterinary guidance supports slow IV aminophylline for acute bronchoconstriction, including as an alternative when inhaled albuterol is unavailable, and direct canine studies establish IV exposure and show safer concentrations with a 15-minute infusion than a 30-second bolus. However, the evidence is mainly consensus and small healthy-dog PK studies rather than modern comparative clinical-outcome trials; inhaled beta2 agonists are generally preferred and aminophylline does not treat airway inflammation or the underlying cause.

Safety and tolerability4.5/10

Aminophylline has a narrow therapeutic index and variable clearance. Rapid IV delivery can cause hypotension, tachyarrhythmia, vomiting, CNS excitation, seizures or death; risk rises with prior methylxanthine exposure, cardiac or seizure disease, fever, shock, hepatic disease and interacting drugs. A controlled slow infusion, ECG/pressure/electrolyte monitoring and serum theophylline measurement when exposure is uncertain make selected short rescue use manageable, but the margin remains limited.

Clinical practicality5.5/10

The 24 mg/ml solution is ready to withdraw and a 10 ml ampoule can cover common medium-to-large canine rescue doses without reconstitution. It still requires accurate lean-weight calculation, controlled dilution/slow IV delivery, venous access and continuous monitoring; small dogs waste much of a single-use ampoule, and the missing exact label requires local verification of compatibility, storage and discard instructions.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Administer intravenously only as a controlled slow injection or infusion; never give a rapid bolus. A canine PK comparison produced a substantially lower immediate theophylline concentration with a 15-minute infusion than with a 30-second bolus.
  • Aminophylline has a narrow therapeutic index. Before a loading dose, establish recent oral or injectable theophylline/aminophylline exposure whenever possible; monitor ECG, perfusion, blood pressure, electrolytes and clinical toxicity, and measure serum theophylline when prior exposure, repeated dosing or impaired clearance makes accumulation plausible.
  • Avoid or use only after a compelling benefit-risk decision in active tachyarrhythmia, uncontrolled seizure disorder, active peptic ulceration or known hypersensitivity to theophyllines/ethylenediamine. Fever, shock, heart failure, hepatic disease and severe systemic illness can reduce clearance and require extra caution.
  • Do not combine with another xanthine preparation unless total exposure and serum concentration are deliberately managed. Concurrent aminophylline plus theophylline from another product or route can produce serious additive toxicity.
  • Fluoroquinolones, macrolides, cimetidine, propranolol and several other inhibitors can raise theophylline exposure; phenobarbital and other enzyme inducers can lower it. Review the full medication list, avoid high-risk combinations when possible and use serum monitoring/dose adjustment when unavoidable.
  • Beta2 agonists, epinephrine and other sympathomimetics may add tachyarrhythmia and hypokalaemia risk. They may still be clinically indicated in an emergency, but combine only with ECG, electrolyte and haemodynamic monitoring rather than assuming bronchodilator effects are simply additive.
  • Aminophylline solutions are alkaline and have important admixture incompatibilities. Do not mix or use a Y-site with another medicine until compatibility has been verified for the exact concentrations and diluent from a current hospital source.
  • This is a rescue bronchodilator, not treatment of airway inflammation, anaphylactic shock, infection, pulmonary oedema or another cause of respiratory distress. Provide oxygen and cause-directed treatment; inhaled beta2 agonists are generally preferred when they can be delivered effectively.
  • Use lean/appropriate body weight, verify that the vial strength is expressed as aminophylline rather than theophylline equivalent, and calculate both milligrams and millilitres independently. Stop or slow administration and reassess vomiting, marked agitation/tremor, hypotension, tachyarrhythmia or seizure activity.
  • Safety of this exact human presentation in pregnant or lactating bitches/queens, neonates and breeding animals is not established. Use only when the monitored rescue benefit clearly outweighs the uncertainty; verify the exact product label, excipients, storage and single-use/discard instructions before administration.
Assessment sources
  1. Biopolus Euphyllin GE register2026
  2. Veterinary aminophylline register audit2026
  3. MSD Vet Manual 20242024
  4. MSD emergency triage2026
  5. Canine/feline triage review2024
  6. Aminophylline injection SmPC2026
  7. Canine IV aminophylline infusion PK2000
  8. Canine IV aminophylline comparator PK2022
  9. Feline IV aminophylline comparator PK2007
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Monitored IV rescue treatment of acute, clinically important bronchospasm when inhaled beta2-agonist treatment is unavailable, inadequate or cannot be delivered; not routine first-line or chronic-airway treatment.
4.9/10
Weak evidence support
vetman assessment

Euphyllin

24 mg/ml (2.4%), 10 ml ampoule, human medicine
Assessed clinical scopeCat · Monitored IV rescue treatment of acute, clinically important bronchospasm when inhaled beta2-agonist treatment is unavailable, inadequate or cannot be delivered; not routine first-line or chronic-airway treatment. · Intravenous
Care settingEmergency or hospital care with venous access, controlled slow infusion, ECG, blood-pressure and electrolyte monitoring and access to serum-theophylline measurement when prior exposure or repeated dosing makes it relevant
vetman score 4.9/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, human · № რ-034469 · Verified on 16 Oct 2026 Off-label use

A possible second-line monitored IV rescue option when an inhaled beta2 agonist cannot be delivered, but feline outcome evidence and exact-product transparency are limited. The narrow therapeutic margin, small required volume and large single-use pack demand precise withdrawal, slow infusion and close ECG/clinical monitoring; continue anti-inflammatory and cause-directed treatment independently.

Regulatory and scientific credibility5.0/10

The exact Biopolus 24 mg/ml 10 ml presentation has a current, sourced Georgian human registration (R-034469), identifiable manufacturer, strength and pack. No exact public product label or dossier was located, and current same-endpoint EU/EEA and GB veterinary-register searches found no aminophylline product; therefore product-specific excipients, handling and pharmacovigilance transparency remain limited and dog/cat use is off-label.

Clinical efficacy5.0/10

Current emergency guidance permits IV aminophylline as an alternative rescue bronchodilator when inhaled albuterol is unavailable, and six healthy cats tolerated a 10 mg/kg IV comparator dose in a PK study. Direct feline clinical-outcome evidence for acute bronchospasm is sparse, the catalogue dose is lower than that study exposure, and inhaled beta2 agonists are generally preferred; aminophylline does not treat airway inflammation or the underlying cause.

Safety and tolerability4.5/10

Aminophylline has a narrow therapeutic index and variable clearance. Rapid IV delivery can cause hypotension, tachyarrhythmia, vomiting, CNS excitation, seizures or death; risk rises with prior methylxanthine exposure, cardiac or seizure disease, fever, shock, hepatic disease and interacting drugs. A controlled slow infusion, ECG/pressure/electrolyte monitoring and serum theophylline measurement when exposure is uncertain make selected short rescue use manageable, but the margin remains limited.

Clinical practicality5.0/10

The ready 24 mg/ml solution avoids reconstitution, but a typical feline dose is only about 1 ml and the 10 ml single-use presentation creates substantial waste. Accurate small-volume withdrawal, controlled slow IV delivery, venous access and continuous monitoring are required, and the missing exact label requires local verification of compatibility, storage and discard instructions.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Administer intravenously only as a controlled slow injection or infusion; never give a rapid bolus. A canine PK comparison produced a substantially lower immediate theophylline concentration with a 15-minute infusion than with a 30-second bolus.
  • Aminophylline has a narrow therapeutic index. Before a loading dose, establish recent oral or injectable theophylline/aminophylline exposure whenever possible; monitor ECG, perfusion, blood pressure, electrolytes and clinical toxicity, and measure serum theophylline when prior exposure, repeated dosing or impaired clearance makes accumulation plausible.
  • Avoid or use only after a compelling benefit-risk decision in active tachyarrhythmia, uncontrolled seizure disorder, active peptic ulceration or known hypersensitivity to theophyllines/ethylenediamine. Fever, shock, heart failure, hepatic disease and severe systemic illness can reduce clearance and require extra caution.
  • Do not combine with another xanthine preparation unless total exposure and serum concentration are deliberately managed. Concurrent aminophylline plus theophylline from another product or route can produce serious additive toxicity.
  • Fluoroquinolones, macrolides, cimetidine, propranolol and several other inhibitors can raise theophylline exposure; phenobarbital and other enzyme inducers can lower it. Review the full medication list, avoid high-risk combinations when possible and use serum monitoring/dose adjustment when unavoidable.
  • Beta2 agonists, epinephrine and other sympathomimetics may add tachyarrhythmia and hypokalaemia risk. They may still be clinically indicated in an emergency, but combine only with ECG, electrolyte and haemodynamic monitoring rather than assuming bronchodilator effects are simply additive.
  • Aminophylline solutions are alkaline and have important admixture incompatibilities. Do not mix or use a Y-site with another medicine until compatibility has been verified for the exact concentrations and diluent from a current hospital source.
  • This is a rescue bronchodilator, not treatment of airway inflammation, anaphylactic shock, infection, pulmonary oedema or another cause of respiratory distress. Provide oxygen and cause-directed treatment; inhaled beta2 agonists are generally preferred when they can be delivered effectively.
  • Use lean/appropriate body weight, verify that the vial strength is expressed as aminophylline rather than theophylline equivalent, and calculate both milligrams and millilitres independently. Stop or slow administration and reassess vomiting, marked agitation/tremor, hypotension, tachyarrhythmia or seizure activity.
  • Safety of this exact human presentation in pregnant or lactating bitches/queens, neonates and breeding animals is not established. Use only when the monitored rescue benefit clearly outweighs the uncertainty; verify the exact product label, excipients, storage and single-use/discard instructions before administration.
Assessment sources
  1. Biopolus Euphyllin GE register2026
  2. Veterinary aminophylline register audit2026
  3. MSD Vet Manual 20242024
  4. MSD emergency triage2026
  5. Canine/feline triage review2024
  6. Aminophylline injection SmPC2026
  7. Canine IV aminophylline infusion PK2000
  8. Canine IV aminophylline comparator PK2022
  9. Feline IV aminophylline comparator PK2007
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Aminophylline24 mg/ml
Formulation Type
Solution
Administration route
Intravenous
Manufacturer
Biopolus
Registration
Georgia Yes, human
In force until 18 Feb 2027
Human (Ministry of Health, RAMA)
In the register: ეუფილინი 24 მგ/მლ (2.4%), 10 მლ ამპულა
№ რ-034469
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
150 mg, Tablet · Cat Cat 5 mg/kg
Adjunctive bronchodilation only for clinically important wheeze/expiratory distress; never use as anti-inflammatory monotherapy or as a substitute for inhaled rescue treatment in status asthmaticus. A typical 5 kg cat needs 25 mg, one sixth of this narrow-index tablet; equal subdivision is not validated, so use a pharmacy-prepared dose or another validated formulation rather than visual splitting.
 · every 12 hours		 every 12 hours Georgia Suspended
Suspended or cancelled
Human (Ministry of Health, RAMA)
In the register: ეუფილინი 150 მგ ტაბლეტები
№ რ-031585
Verified on: 22 Oct 2026
150 mg, Tablet · Dog Dog 10 mg/kg
Adjunctive bronchodilation only when clinically important bronchospasm is present; do not substitute for diagnosis, inhaled rescue treatment when appropriate, or anti-inflammatory/cause-directed therapy. One whole 150 mg tablet exactly fits 15 kg; other weights usually require a pharmacy-prepared immediate-release dose because dose-accurate equal subdivision of the exact tablet is unvalidated.
 · every 8 hours		 every 8 hours Georgia Suspended
Suspended or cancelled
Human (Ministry of Health, RAMA)
In the register: ეუფილინი 150 მგ ტაბლეტები
№ რ-031585
Verified on: 22 Oct 2026
Details: pack, label wording, sources, registration

Euphyllin 150 mg, Tablet

tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Oral adjunctive bronchodilation for diagnosed canine chronic lower-airway disease or intrathoracic airway collapse with clinically important reversible bronchospasm
3.9/10
Poor / unconvincing
vetman assessment

Euphyllin

150 mg, tablet, human medicine
Assessed clinical scopeDog · Oral adjunctive bronchodilation for diagnosed canine chronic lower-airway disease or intrathoracic airway collapse with clinically important reversible bronchospasm · By mouth
Care settingVeterinarian-selected outpatient adjunct after diagnosis, with a dose-accurate immediate-release preparation, interaction review, toxicity counselling and serum/clinical monitoring when risk or response warrants it.
vetman score 3.9/10 Poor / unconvincing
Evidence confidence: Low Georgia: Suspended · № რ-031585 · Verified on 22 Oct 2026 Off-label use

A pharmacologically credible but weakly evidenced oral adjunct whose exact human tablet is no longer actively authorised in Georgia. Narrow therapeutic margin, q8h dosing and a 150 mg unit without validated equal subdivision make it a poor practical choice for many dogs; use only for a defined bronchospastic role with accurate preparation and monitoring, never instead of anti-inflammatory or cause-directed treatment.

Regulatory and scientific credibility4.0/10

Exact identity, composition and a current Russian human register trace are verifiable, but Georgian authorisation expired while suspended, no veterinary aminophylline authorisation was located in the audited EU/EEA and GB registers, and no exact-product dog/cat dossier or clinical trial exists; the formulation-evidence gate caps this axis.

Clinical efficacy4.0/10

Current professional guidance retains oral aminophylline dosing and a plausible adjunctive role, but support is mainly class pharmacology and old small PK work rather than comparative canine clinical outcomes; it is less effective than anti-inflammatory treatment and not a first-line substitute for inhaled options.

Safety and tolerability4.0/10

The exact human label and class risks are known, but the margin is narrow and dog-specific repeated-dose safety for this tablet is absent; GI, CNS and cardiac toxicity, variable clearance and multiple common interactions require careful selection and monitoring.

Clinical practicality3.5/10

Every-eight-hour home dosing is burdensome and the 150 mg unit exactly fits only a 15 kg dog at 10 mg/kg; because equal subdivision is unvalidated, most small and many medium dogs need an accurately compounded immediate-release dose rather than visual thirds or two-thirds.

Full-course cost-effectiveness-

A current Georgian exact-pack price and patient-weight-adjusted full-course cost were not verified; price is excluded from the denominator.

Important safety and use flags

  • Narrow therapeutic index: stop and reassess vomiting, diarrhoea, marked agitation, tremor, tachycardia/arrhythmia or seizure. Toxicosis can occur below the human-derived 20 mcg/ml upper therapeutic target.
  • Do not estimate one third, two thirds or one sixth by eye. The exact label does not validate dose-accurate equal subdivision or crushing; use a pharmacy-prepared immediate-release form when one whole tablet does not fit.
  • Avoid duplicate theophylline/aminophylline or another xanthine unless total exposure and serum concentration are deliberately managed; additive toxicity can be severe.
  • Macrolides, cimetidine, propranolol, enrofloxacin, marbofloxacin and other metabolic inhibitors can raise exposure; review every medicine and reduce/monitor or avoid the combination as appropriate.
  • Rifampin, phenobarbital and other enzyme inducers can lower exposure and apparent response. Do not compensate empirically without reassessing diagnosis, adherence, formulation and serum concentration when available.
  • Avoid or use only after a compelling benefit-risk decision in active tachyarrhythmia, uncontrolled seizure disorder, active GI ulceration or known hypersensitivity to theophyllines or ethylenediamine.
  • Fever, hepatic disease, heart failure, shock and severe systemic illness can reduce clearance. Consider serum theophylline measurement after steady state, dose/formulation change, suspected toxicity or a clinically important clearance interaction.
  • Beta2 agonists, epinephrine and other sympathomimetics can add tachyarrhythmia and hypokalaemia risk. Combine only when clinically justified, with heart-rate/rhythm and electrolyte assessment appropriate to severity.
  • This is adjunctive bronchodilation, not treatment of airway inflammation, infection, pulmonary oedema, anaphylaxis or another cause of respiratory signs. Confirm reversible bronchospasm and continue cause-directed treatment independently.
  • Repeated-dose safety of this exact human tablet is not established in pregnant/lactating animals, juveniles, breeding animals or dogs/cats with organ disease. The exact label does not validate crushing, feeding-tube administration or compounded stability.
Assessment sources
  1. GE Euphyllin audit2026
  2. RU Euphyllin register2025
  3. Euphyllin tablet label2026
  4. Veterinary aminophylline register audit2026
  5. MSD Vet Manual 20242024
  6. Feline aminophylline PK1983
  7. Canine aminophylline PK1988
  8. Feline airway therapy review2023
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Oral adjunctive bronchodilation for diagnosed feline inflammatory lower-airway disease with clinically important wheeze or expiratory bronchospasm
3.3/10
Poor / unconvincing
vetman assessment

Euphyllin

150 mg, tablet, human medicine
Assessed clinical scopeCat · Oral adjunctive bronchodilation for diagnosed feline inflammatory lower-airway disease with clinically important wheeze or expiratory bronchospasm · By mouth
Care settingVeterinarian-selected outpatient adjunct after diagnosis, with a dose-accurate immediate-release preparation, interaction review, toxicity counselling and serum/clinical monitoring when risk or response warrants it.
vetman score 3.3/10 Poor / unconvincing
Evidence confidence: Low Georgia: Suspended · № რ-031585 · Verified on 22 Oct 2026 Off-label use

Oral exposure is plausible, but exact-product outcome evidence is absent and the 150 mg tablet without validated equal subdivision is profoundly mismatched to a typical feline 25 mg dose. Narrow margin, interactions and bezoar-retention risk make routine visual fractioning unacceptable; use only as a veterinarian-selected adjunct with a pharmacy-prepared dose and independent anti-inflammatory treatment.

Regulatory and scientific credibility4.0/10

Exact identity, composition and a current Russian human register trace are verifiable, but Georgian authorisation expired while suspended, no veterinary aminophylline authorisation was located in the audited EU/EEA and GB registers, and no exact-product dog/cat dossier or clinical trial exists; the formulation-evidence gate caps this axis.

Clinical efficacy3.5/10

Old feline multiple-dose pharmacokinetics show 96% oral bioavailability, but no exact-tablet clinical outcome trial establishes benefit; current feline guidance restricts bronchodilators to clinically important bronchospasm and does not support them as anti-inflammatory monotherapy.

Safety and tolerability3.5/10

The margin is narrow, feline exact-product repeated-dose safety is absent, and retained tablets in bezoars may continue absorption; GI, CNS and cardiac toxicity, variable clearance and common interactions make inaccurate fractional dosing particularly consequential.

Clinical practicality1.5/10

Every-12-hour dosing is feasible, but a typical 5 kg cat needs 25 mg—one sixth of a 150 mg narrow-index tablet whose equal subdivision is unvalidated—so the supplied unit is not dose-accurate for routine feline use without pharmacy compounding.

Full-course cost-effectiveness-

A current Georgian exact-pack price and patient-weight-adjusted full-course cost were not verified; price is excluded from the denominator.

Important safety and use flags

  • Narrow therapeutic index: stop and reassess vomiting, diarrhoea, marked agitation, tremor, tachycardia/arrhythmia or seizure. Toxicosis can occur below the human-derived 20 mcg/ml upper therapeutic target.
  • Do not estimate one third, two thirds or one sixth by eye. The exact label does not validate dose-accurate equal subdivision or crushing; use a pharmacy-prepared immediate-release form when one whole tablet does not fit.
  • Avoid duplicate theophylline/aminophylline or another xanthine unless total exposure and serum concentration are deliberately managed; additive toxicity can be severe.
  • Macrolides, cimetidine, propranolol, enrofloxacin, marbofloxacin and other metabolic inhibitors can raise exposure; review every medicine and reduce/monitor or avoid the combination as appropriate.
  • Rifampin, phenobarbital and other enzyme inducers can lower exposure and apparent response. Do not compensate empirically without reassessing diagnosis, adherence, formulation and serum concentration when available.
  • Avoid or use only after a compelling benefit-risk decision in active tachyarrhythmia, uncontrolled seizure disorder, active GI ulceration or known hypersensitivity to theophyllines or ethylenediamine.
  • Fever, hepatic disease, heart failure, shock and severe systemic illness can reduce clearance. Consider serum theophylline measurement after steady state, dose/formulation change, suspected toxicity or a clinically important clearance interaction.
  • Beta2 agonists, epinephrine and other sympathomimetics can add tachyarrhythmia and hypokalaemia risk. Combine only when clinically justified, with heart-rate/rhythm and electrolyte assessment appropriate to severity.
  • This is adjunctive bronchodilation, not treatment of airway inflammation, infection, pulmonary oedema, anaphylaxis or another cause of respiratory signs. Confirm reversible bronchospasm and continue cause-directed treatment independently.
  • Repeated-dose safety of this exact human tablet is not established in pregnant/lactating animals, juveniles, breeding animals or dogs/cats with organ disease. The exact label does not validate crushing, feeding-tube administration or compounded stability.
Assessment sources
  1. GE Euphyllin audit2026
  2. RU Euphyllin register2025
  3. Euphyllin tablet label2026
  4. Veterinary aminophylline register audit2026
  5. MSD Vet Manual 20242024
  6. Feline aminophylline PK1983
  7. Canine aminophylline PK1988
  8. Feline airway therapy review2023
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Aminophylline150 mg
Formulation Type
Tablet
Administration route
By mouth
Registration
Georgia Suspended
Suspended or cancelled
Human (Ministry of Health, RAMA)
In the register: ეუფილინი 150 მგ ტაბლეტები
№ რ-031585
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified Human immediate-release tablet; all dog/cat use is off-label. Current MSD aminophylline doses: dog 10 mg/kg PO every 8 hours; cat 5 mg/kg PO every 12 hours. The exact label does not validate equal tablet subdivision or crushing. One whole tablet fits a 15 kg dog at 10 mg/kg; a 10 kg dog needs 100 mg (two thirds), a 5 kg dog 50 mg (one third), and a 5 kg cat 25 mg (one sixth). Do not estimate those fractions visually because dose-accurate equal subdivision has not been validated for this narrow-index tablet; use a pharmacy-prepared immediate-release dose or another validated formulation.
DoseSpeciesWeightRouteFrequencySource
5 mg/kg
Adjunctive bronchodilation only for clinically important wheeze/expiratory distress; never use as anti-inflammatory monotherapy or as a substitute for inhaled rescue treatment in status asthmaticus. A typical 5 kg cat needs 25 mg, one sixth of this narrow-index tablet; equal subdivision is not validated, so use a pharmacy-prepared dose or another validated formulation rather than visual splitting.
 Cat Any weight By mouth every 12 hours
MSD Vet Manual 2024
Reference book
A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose.
Systemic Treatment of Inflammatory Airway Disease in Animals
MSD/Merck Veterinary Manual, 2024
10 mg/kg
Adjunctive bronchodilation only when clinically important bronchospasm is present; do not substitute for diagnosis, inhaled rescue treatment when appropriate, or anti-inflammatory/cause-directed therapy. One whole 150 mg tablet exactly fits 15 kg; other weights usually require a pharmacy-prepared immediate-release dose because dose-accurate equal subdivision of the exact tablet is unvalidated.
 Dog Any weight By mouth every 8 hours
MSD Vet Manual 2024
Reference book
A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose.
Systemic Treatment of Inflammatory Airway Disease in Animals
MSD/Merck Veterinary Manual, 2024

Aminophylline: No dose supported by a publicly verifiable source yet

Known Contraindications

  • Critical
    Known hypersensitivity to aminophylline, theophylline, or ethylenediamine is a contraindication.
  • Warning
    toxicosis may occur with concentrations < 20 mcg/mL
    Sources: MSD Vet Manual
  • Warning
    IV (slow)
    Sources: MSD Vet Manual
  • Warning
    Use cautiously in an existing arrhythmia because methylxanthines increase heart rate and are arrhythmogenic.
  • Warning
    Use cautiously in seizure disorders because methylxanthines lower the seizure threshold and seizures are also a manifestation of toxicity.

Known Drug Interactions

  • Major warning Enrofloxacin + Aminophylline
    Theophylline metabolism is inhibited by erythromycin, cimetidine, propranolol, enrofloxacin, and marbofloxacin
    Recommendation: Reduce the aminophylline dose during concomitant use. Signs of toxicity include vomiting, excitation, tachyarrhythmia, and seizures.
    Sources: MSD Vet Manual
  • Major warning Marbofloxacin + Aminophylline
    Theophylline metabolism is inhibited by... enrofloxacin, and marbofloxacin
    Recommendation: Reduce the aminophylline dose during concomitant use. Signs of toxicity include vomiting, excitation, tachyarrhythmia, and seizures.
    Sources: MSD Vet Manual
  • Major warning Ciprofloxacin + Aminophylline
    Serious and fatal reactions have been reported in patients receiving concurrent administration of CIPRO and theophylline. These reactions have included cardiac arrest, seizure, status epilepticus, and respiratory failure. Avoid Use (Plasma Exposure Likely to be Increased and Prolonged)
    Recommendation: Avoid concurrent use when possible. If the combination is unavoidable, monitor serum theophylline and reduce the aminophylline dose as needed. Watch for nausea, vomiting, tremor, excitation, tachycardia, and seizures.
    Sources: FDA
  • Major warning Phenobarbital + Aminophylline
    induced by rifampin and phenobarbital
    Recommendation: Monitor the bronchodilator response; a dose increase may be necessary.
    Sources: MSD Vet Manual

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗